■特应性皮炎(AD)的生殖器受累会对患者的生活质量产生重大影响。然而,在常规检查期间通常不进行生殖器区域的检查,患者可能不愿意通知临床医生或显示该区域。
■评价曲洛金单抗在AD患者生殖器受累中的疗效。
■已分析了接受曲洛金单抗治疗的中度/重度AD和生殖器受累的成年患者。主要终点是EASI,DLQI,PP-NRS,第16周生殖器-IGA(g-IGA)和生殖器瘙痒(GI)。
■在接受曲洛金单抗治疗的48例中度/重度AD患者中,12例患者(25%)表现出生殖器受累。7名患者报告生殖器区域瘙痒(58%),而没有报告生殖器感染的阳性病史。T0时的中位数为EASI17.5、PP-NRS8和DLQI14。治疗16周后,我们观察到EASI中位数为3,PP-NRS中位数为1,DLQI中位数为1.最后,关于生殖器反应,治疗16周后,我们观察到平均GI和g-IGA评分有统计学显著下降.
■尽管我们的样品尺寸很小,tralokinumab可以被认为是生殖器受累的AD的有效治疗选择。
UNASSIGNED: Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient\'s quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.
UNASSIGNED: to evaluate the efficacy of tralokinumab in AD patients with genital involvement.
UNASSIGNED: Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.
UNASSIGNED: out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.
UNASSIGNED: despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.